I-JanOne Inc., inkampani egxile ekwakhiweni kwezidakamizwa ezinezakhiwo ezingaluthiki, ezidambisa izinhlungu - emzamweni wokunciphisa ubhadane lokuluthwa izidakamizwa - ngaphambilini yamemezela isivumelwano senketho samalungelo esu elinoveli lokunciphisa i-methamphetamine ( meth) sebenzisa ngokuvula i-Translocator Protein 18 kDa (TSPO).
Nakuba imakethe ehlongozwayo yokwelashwa kokuhlukunyezwa kwe-methamphetamine isondele ku-$500M, ayikho imithi egunyazwe yi-FDA yokwelapha ukuphazamiseka kokusebenzisa i-methamphetamine.
“Sijabule kakhulu ngokuqala ucwaningo lwethu ekwelashweni okusha kwe-methamphetamine disorder,” kuphawula uTony Isaac, Isikhulu Esiphezulu se-JanOne Inc. “Umgomo we-JanOne uwukuba nomthelela enkingeni ye-opioid eMelika. Njengoba abasebenzisi be-meth abangaphezu kuka-40% ngesikhathi esisodwa besebenzisa i-opioid, sinethemba lokuthi lolu hlelo ngeke lube nomthelela enkingeni ye-meth kuphela, kodwa futhi lubambe iqhaza ekwehliseni ukuhlukunyezwa nokufa kwe-opioid.”
I-JanOne Inc. ihlonze abahlanganyeli abasezingeni lomhlaba futhi ilindele ukuqalisa uhlelo lokutholwa kwezidakamizwa ngo-2022, ngenhloso yokuhlonza umuntu ozokhethwa ngaphambi kwe-IND ngo-2023. Lokhu kumelela umzamo owengeziwe wokwelapha epayipini le-JanOne Inc., nenkampani elindele ukuhlolwa. ukuqala isivivinyo esibucayi seSigaba 2b nge-JAN101 ngasekupheleni kuka-2022.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- has identified world-class collaborators and anticipates initiating a drug discovery program in 2022, with the goal of identifying a preclinical IND-candidate in 2023.
- Nakuba imakethe ehlongozwayo yokwelashwa kokuhlukunyezwa kwe-methamphetamine isondele ku-$500M, ayikho imithi egunyazwe yi-FDA yokwelapha ukuphazamiseka kokusebenzisa i-methamphetamine.
- Previously announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).
